Clinical Trial Update: A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating Octagam 5% in pediatric acute-onset neuropsychiatric syndrome (PANS) and related autoimmune neuropsychiatric conditions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute-onset Neuropsychiatric Syndrome
• Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections

Drugs mentioned

• Octagam 5% (intravenous immunoglobulin G (IVIG) 5%)

Snippet

Sponsor: IMMUNOe Research Centers | Conditions: Pediatric Acute-Onset Neuropsychiatric Syndrome, Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections | Phase 4 | Status: UNKNOWN